Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Common Equity (2016 - 2025)

CytomX Therapeutics' Common Equity history spans 12 years, with the latest figure at $99.0 million for Q4 2025.

  • For Q4 2025, Common Equity rose 21812.28% year-over-year to $99.0 million; the TTM value through Dec 2025 reached $99.0 million, up 21812.28%, while the annual FY2025 figure was $99.0 million, 21812.28% up from the prior year.
  • Common Equity reached $99.0 million in Q4 2025 per CTMX's latest filing, down from $107.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $119.9 million in Q2 2025 to a low of -$86.6 million in Q1 2023.
  • Average Common Equity over 5 years is -$4.4 million, with a median of -$26.6 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 18582.14% in 2022, then surged 21812.28% in 2025.
  • A 5-year view of Common Equity shows it stood at -$459000.0 in 2021, then tumbled by 18582.14% to -$85.8 million in 2022, then soared by 44.67% to -$47.4 million in 2023, then soared by 99.04% to -$456000.0 in 2024, then soared by 21812.28% to $99.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Common Equity are $99.0 million (Q4 2025), $107.4 million (Q3 2025), and $119.9 million (Q2 2025).